ClinicalTrials.gg
TerminatedNCT02151903Updated Nov 27, 2020Results posted

Open-Label Extension Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered in Participants With B-cell NHL

A Phase 1/2 interventional study of DI-Leu16-IL2 in B-cell Non-Hodgkin Lymphoma, sponsored by Alopexx Oncology, LLC. Terminated at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-11-27.

Sponsored by Alopexx Oncology, LLC · Phase 1/2, Interventional, and Treatment

How we know

Why this study was terminated
Clinical benefit was noted before the scheduled completion of the trial and the extension study was terminated early.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
5
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 399 studies in Lymphoma, B-Cell with a site in United States — 91 open to participants now, 157 under way, 12 of them phase 3. Lymphoma, B-Cell · United States.

Enrollment
345th of 381
5 · median 37
Started
2014
with 9 others
Phase 1/2
75 of 399
20 open now
Registered
120th of 399
by date

Among the 399 studies in Lymphoma, B-Cell with a site in United States, this one is the 345th largest by enrollment of the 381 interventional ones that give a count, is one of 10 that started in 2014, is one of 75 in phase 1/2, and was the 120th registered.

Lymphoma, B-Cell

889 studies on the registry are indexed under Lymphoma, B-Cell; 289 are open to participants now.

Browse Lymphoma, B-Cell studies →

Open to participants now

91 of the 399 studies in Lymphoma, B-Cell with a site in United States are open now. Recruiting first, the newest first:

86 more — sign in →

All 91 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 209 Lymphoma, B-Cell studies recruiting now, 128 (61%) set no upper age limit and 61 (29%) stop at 75 or younger; 37 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 399 studies in Lymphoma, B-Cell with a site in United States, or all of them as a file.
02

Study summary

This is an open-label extension study enrolling participants experiencing clinical benefit following 6 cycles of DI-Leu16-IL2 while enrolled in the Alopexx Oncology Dose-Escalation AO-101 study (NCT01874288). Participants will be permitted to continue to receive DI-Leu16-IL2 at the same dose, schedule, and route of administration they received during Study AO-101 (Main Study). Prior pre-treatment (for example, Rituximab) will continue as before.

03

Conditions studied

  • B-cell Non-Hodgkin Lymphoma

Keywords

  • NHL
  • Immunocytokine
  • Lymphoma
  • Non-Hodgkin
  • B-cell
  • IL (interleukin)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants currently entered on Alopexx Oncology Study AO-101
  2. Participants who received 6 cycles of DI-Leu16-IL2 on Study AO-101.
  3. Documented clinical benefit following 6th cycle of DI-Leu16-IL2
  4. Able to begin extension study within 8 weeks of receiving 6th cycle of DI-Leu16-IL2
  5. Participants must have received prior Rituximab-containing therapy.
  6. Participants in this extension study are to use adequate measures (abstinence, oral contraceptives, barrier method with spermicide or surgical sterilization) during the study. Females of must have a negative serum pregnancy test on the days of dosing. A female of childbearing potential: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally for at least 24 consecutive months (that is, has had menses at any time in the preceding 24 consecutive months.
  7. Provide written prior to any study procedures.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or lactating female
  2. An immediate need for palliative radiotherapy or systemic therapy.
  3. Actively infected with or chronic carriers of virus (HBV) as demonstrated by positive hepatitis B core antibody (HbcAb) or hepatitis B surface antigen (HbsAg). Participants who are sero-positive only, that is, surface antibody positive [HbsAb], are permitted.
  4. Other significant active infection
  5. Major surgery, chemotherapy, agent, or radiation within 30 days of Day 1
  6. Uncontrolled hypertension (diastolic ≥ 100 millimeters of mercury [mmHg]) or hypotension (systolic ≤ 90 mmHg)
  7. History of prior therapy or a serious, uncontrolled medical disorder that in the Investigator's opinion would impair participation in the study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
5 participants (actual)

Study arms

  • Experimental
    DI-Leu16-IL2 1.0 mg/m^2

    Participants will receive DI-Leu16-IL2 1.0 milligrams per square meter (mg/m\^2) subcutaneously (SC) for 3 consecutive days every 3 weeks (21-day cycle). Participants will continue to receive therapy through the duration of the study as long as they will have clinical benefit and will not experience any untoward side effects.

    Drug: DI-Leu16-IL2

  • Experimental
    DI-Leu16-IL2 2.0 mg/m^2

    Participants will receive DI-Leu16-IL2 2.0 mg/m\^2 SC for 3 consecutive days every 3 weeks (21-day cycle). Participants will continue to receive therapy through the duration of the study as long as they will have clinical benefit and will not experience any untoward side effects.

    Drug: DI-Leu16-IL2

Interventions

  • DI-Leu16-IL2 will be administered per dose and schedule specified in the arm.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Best Overall Response (BOR) Assessed Per International Workshop for Non-Hodgkin Lymphoma (NHL) Response Criteria

    BOR included complete response (CR), unconfirmed CR (CRu), partial response (PR), stable disease (SD), and progressive disease (PD). CR: 1)Disappearance of all detectable clinical and radiological evidence of disease; 2)lymph nodes (LN) regressed to normal size; 3)other organs (spleen, liver, kidneys) that were enlarged before therapy must have decreased in size; 4)clear bone marrow(BM) infiltrate. CRu: must meet CR criteria 1 and 3, as well as ≥1 of following: residual LN mass \>1.5 centimeters (cm) in greatest transverse diameter; individual nodes that were previously confluent regressed by \>75% in sum of product diameters (SPD); or indeterminate BM. PR: 6 largest dominant nodes or nodal masses decreased by ≤50% in SPD; no increase in size of other nodes; liver or spleen; splenic and hepatic nodules regressed ≥50% in SPD; and no new disease. SD: less than a PR but not PD. PD: 50% increase from nadir in SPD of any abnormal node for PR or nonresponders and appearance of any new lesion.

    Time frame: First dose of study drug until first appearance of CR, CRu, PR, SD, or PD (up to 20 months)

  2. Tumor Measurement: Percent Change From Baseline in Sum of Product of Diameters at the End of Study

    Sum of product diameters sums the product of the 2 tumor measurements on each lesion. If only 1 measurement was available, it was used as the longest length and the product of the lengths in the sum. Baseline value is the last non-missing measurement prior to receiving study drug injection in the Main Study AO-101.

    Time frame: Baseline, end of study (EOS) (up to approximately 32 months)

  3. Tumor Measurement: Percent Change From Baseline in Sum of Longest Diameters at the End of Study

    Sum of longest diameters is the sum of the longest measured length of each tumor lesion. Baseline value is the last non-missing measurement prior to receiving study drug injection in the Main Study AO-101. None of the participants were considered evaluable in 'DI-Leu16-IL2 2.0 mg/m\^2' arm for this outcome measure at the end of study, and therefore, data were not collected for that arm

    Time frame: Baseline, EOS (up to approximately 32 months)

Secondary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. TEAEs were defined as AEs with onset at the time of or following the start of treatment with study drug, or AEs starting before the start of treatment but increasing in severity or relationship at the time of or following the start of treatment. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.

    Time frame: First dose of study drug up to EOS (up to 20 months)

  2. Number of Participants With a TEAE That Was Considered Related to a Clinically Significant Hematology or Serum Chemistry Abnormality

    TEAEs were defined as AEs with onset at the time of or following the start of treatment with study drug, or AEs starting before the start of treatment but increasing in severity or relationship at the time of or following the start of treatment. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section. Clinically significant hematology and serum chemistry abnormalities were identified at the Investigator's discretion.

    Time frame: First dose of study drug up to EOS (up to 20 months)

  3. Number of Participants With a Clinically Significant Abnormal Physical Exam

    Clinically significant abnormal physical exams included extremities, head, ears, eyes, nose, throat, abdomen, respiratory system, lymphatic system, and integumentary system. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section. Clinically significant abnormal physical exams were identified at the Investigator's discretion.

    Time frame: First dose of study drug up to EOS (up to 20 months)

07

Results

Posted Nov 27, 2020
Limitations and caveats
Clinical benefit was noted before the scheduled completion of the trial, hence; the study was terminated early.

Participant flow

Participants who, in the opinion of the Investigator, exhibited a beneficial effect without a dose-limiting toxicity (DLT) in the dose-escalation Study AO-101 (NCT01874288) (Main Study) were allowed to continue treatment with DI-Leu16-IL2 in this open-label extension study.

Participant flow — Overall Study
MilestoneDI-Leu16-IL2 1.0 mg/m^2DI-Leu16-IL2 2.0 mg/m^2
Started32
Received at least 1 dose of study drug32
Completed01
Not completed31
Withdrew: Withdrawal by subject10
Withdrew: Progressive disease21

Outcome measures

PrimaryNumber of Participants With Best Overall Response (BOR) Assessed Per International Workshop for Non-Hodgkin Lymphoma (NHL) Response Criteria

BOR included complete response (CR), unconfirmed CR (CRu), partial response (PR), stable disease (SD), and progressive disease (PD). CR: 1)Disappearance of all detectable clinical and radiological evidence of disease; 2)lymph nodes (LN) regressed to normal size; 3)other organs (spleen, liver, kidneys) that were enlarged before therapy must have decreased in size; 4)clear bone marrow(BM) infiltrate. CRu: must meet CR criteria 1 and 3, as well as ≥1 of following: residual LN mass \>1.5 centimeters (cm) in greatest transverse diameter; individual nodes that were previously confluent regressed by \>75% in sum of product diameters (SPD); or indeterminate BM. PR: 6 largest dominant nodes or nodal masses decreased by ≤50% in SPD; no increase in size of other nodes; liver or spleen; splenic and hepatic nodules regressed ≥50% in SPD; and no new disease. SD: less than a PR but not PD. PD: 50% increase from nadir in SPD of any abnormal node for PR or nonresponders and appearance of any new lesion.

Time frame:
First dose of study drug until first appearance of CR, CRu, PR, SD, or PD (up to 20 months)
Reported as:
Count of participants · Participants
Number of Participants With Best Overall Response (BOR) Assessed Per International Workshop for Non-Hodgkin Lymphoma (NHL) Response Criteria
ParticipantsDI-Leu16-IL2 1.0 mg/m^2DI-Leu16-IL2 2.0 mg/m^2
CR01
CRu00
PR00
SD10
PD11
PrimaryTumor Measurement: Percent Change From Baseline in Sum of Product of Diameters at the End of Study

Sum of product diameters sums the product of the 2 tumor measurements on each lesion. If only 1 measurement was available, it was used as the longest length and the product of the lengths in the sum. Baseline value is the last non-missing measurement prior to receiving study drug injection in the Main Study AO-101.

Time frame:
Baseline, end of study (EOS) (up to approximately 32 months)
Reported as:
Mean · percent change
Tumor Measurement: Percent Change From Baseline in Sum of Product of Diameters at the End of Study
percent changeDI-Leu16-IL2 1.0 mg/m^2DI-Leu16-IL2 2.0 mg/m^2
Tumor Measurement: Percent Change From Baseline in Sum of Product of Diameters at the End of Study-22.86066 ± 9.805965—
PrimaryTumor Measurement: Percent Change From Baseline in Sum of Longest Diameters at the End of Study

Sum of longest diameters is the sum of the longest measured length of each tumor lesion. Baseline value is the last non-missing measurement prior to receiving study drug injection in the Main Study AO-101. None of the participants were considered evaluable in 'DI-Leu16-IL2 2.0 mg/m\^2' arm for this outcome measure at the end of study, and therefore, data were not collected for that arm

Time frame:
Baseline, EOS (up to approximately 32 months)
Reported as:
Mean · percent change
Tumor Measurement: Percent Change From Baseline in Sum of Longest Diameters at the End of Study
percent changeDI-Leu16-IL2 1.0 mg/m^2DI-Leu16-IL2 2.0 mg/m^2
Tumor Measurement: Percent Change From Baseline in Sum of Longest Diameters at the End of Study-11.638 ± 1.5001—
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. TEAEs were defined as AEs with onset at the time of or following the start of treatment with study drug, or AEs starting before the start of treatment but increasing in severity or relationship at the time of or following the start of treatment. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.

Time frame:
First dose of study drug up to EOS (up to 20 months)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
ParticipantsDI-Leu16-IL2 1.0 mg/m^2DI-Leu16-IL2 2.0 mg/m^2
Any TEAEs31
SAEs20
SecondaryNumber of Participants With a TEAE That Was Considered Related to a Clinically Significant Hematology or Serum Chemistry Abnormality

TEAEs were defined as AEs with onset at the time of or following the start of treatment with study drug, or AEs starting before the start of treatment but increasing in severity or relationship at the time of or following the start of treatment. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section. Clinically significant hematology and serum chemistry abnormalities were identified at the Investigator's discretion.

Time frame:
First dose of study drug up to EOS (up to 20 months)
Reported as:
Count of participants · Participants
Number of Participants With a TEAE That Was Considered Related to a Clinically Significant Hematology or Serum Chemistry Abnormality
ParticipantsDI-Leu16-IL2 1.0 mg/m^2DI-Leu16-IL2 2.0 mg/m^2
Number of Participants With a TEAE That Was Considered Related to a Clinically Significant Hematology or Serum Chemistry Abnormality30
SecondaryNumber of Participants With a Clinically Significant Abnormal Physical Exam

Clinically significant abnormal physical exams included extremities, head, ears, eyes, nose, throat, abdomen, respiratory system, lymphatic system, and integumentary system. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section. Clinically significant abnormal physical exams were identified at the Investigator's discretion.

Time frame:
First dose of study drug up to EOS (up to 20 months)
Reported as:
Count of participants · Participants
Number of Participants With a Clinically Significant Abnormal Physical Exam
ParticipantsDI-Leu16-IL2 1.0 mg/m^2DI-Leu16-IL2 2.0 mg/m^2
Number of Participants With a Clinically Significant Abnormal Physical Exam31

Adverse events

Collected over First dose of study drug up to EOS (up to 20 months). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DI-Leu16-IL2 1.0 mg/m^20/3 (0%)2/3 (66.7%)3/3 (100%)
DI-Leu16-IL2 2.0 mg/m^20/2 (0%)0/2 (0%)1/2 (50%)
Most frequent serious events
Most frequent serious events
EventDI-Leu16-IL2 1.0 mg/m^2DI-Leu16-IL2 2.0 mg/m^2
AnaemiaBlood and lymphatic system disorders1/30/2
MelenaGastrointestinal disorders1/30/2
Most frequent other events
Showing 10 of 63
Most frequent other events
EventDI-Leu16-IL2 1.0 mg/m^2DI-Leu16-IL2 2.0 mg/m^2
FallInjury, poisoning and procedural complications2/30/2
Dry mouthGastrointestinal disorders1/31/2
Injection site erythemaGeneral disorders1/31/2
Injection site indurationGeneral disorders1/31/2
InsomniaPsychiatric disorders1/31/2
HypotensionVascular disorders1/31/2
Injection site pruritusGeneral disorders1/31/2
Injection site swellingGeneral disorders1/31/2
Upper respiratory tract infectionInfections and infestations1/31/2
Cerumen impactionEar and labyrinth disorders0/31/2

Baseline characteristics

Safety population included all enrolled participants who received at least 1 dose of study drug.

Age, Categorical
Age, Categorical(Participants)DI-Leu16-IL2 1.0 mg/m^2DI-Leu16-IL2 2.0 mg/m^2Total
<=18 years000
Between 18 and 65 years202
>=65 years123
Sex: Female, Male
Sex: Female, Male(Participants)DI-Leu16-IL2 1.0 mg/m^2DI-Leu16-IL2 2.0 mg/m^2Total
Female123
Male202
08

Study locations

3 sites
  • City of Hope
    Duarte, California 91010, United States
  • University of Minnesota
    Minneapolis, Minnesota 55455, United States
  • Dartmouth-Hitchcock Medical Center
    Lebanon, New Hampshire 03756, United States
09

References and documents

Publications

  • Ko YJ, Bubley GJ, Weber R, Redfern C, Gold DP, Finke L, Kovar A, Dahl T, Gillies SD. Safety, pharmacokinetics, and biological pharmacodynamics of the immunocytokine EMD 273066 (huKS-IL2): results of a phase I trial in patients with prostate cancer. J Immunother. 2004 May-Jun;27(3):232-9. doi: 10.1097/00002371-200405000-00008. PubMed 15076141 ↗
  • King DM, Albertini MR, Schalch H, Hank JA, Gan J, Surfus J, Mahvi D, Schiller JH, Warner T, Kim K, Eickhoff J, Kendra K, Reisfeld R, Gillies SD, Sondel P. Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients. J Clin Oncol. 2004 Nov 15;22(22):4463-73. doi: 10.1200/JCO.2004.11.035. Epub 2004 Oct 13. PubMed 15483010 ↗
  • Maloney DG, Liles TM, Czerwinski DK, Waldichuk C, Rosenberg J, Grillo-Lopez A, Levy R. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood. 1994 Oct 15;84(8):2457-66. PubMed 7522629 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2014 to primary completion in Jul 2016, 20 months.

Results were first posted in Nov 2020, 4 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 23, 2014
First posted
Jun 2, 2014
StartActual
Nov 4, 2014
Primary completionActual
Jul 11, 2016
CompletionActual
Jul 11, 2016
Results first posted
Nov 27, 2020
Last update
Nov 27, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 27, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02151903
Lead sponsor
Alopexx Oncology, LLC
Responsible party
Sponsor
First posted
Jun 2, 2014
Start date
Nov 4, 2014
Primary completion
Jul 11, 2016
Completion
Jul 11, 2016
Results posted
Nov 27, 2020
Last update
Nov 27, 2020

Study contacts

Daniel Vlock, MD
study director · Alopexx Oncology, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: DI-LEU16-IL2

Start the discussion